Ascletis Submits IND Application to the U.S. FDA for ASC36_37o FDC, a Potentially First-in-Class Once-Weekly Oral Quadruple Peptide Agonist Targeting Amylin Receptor, GLP-1R, GIPR and GCGR, for the Treatment of Obesity

Ascletis has submitted an investigational new drug application to the U.S. Food and Drug Administration for ASC36_37o FDC, an oral drug candidate for obesity. The company describes it as a potentially first-in-class, once-weekly pill designed to target four receptors associated with weight regulation: amylin, GLP-1, GIP and glucagon. The filing seeks to advance the candidate toward clinical testing in the United States.
Ad
0Like0Dislike0Comments0Shares


Comments 0
No comments yet. Be the first to share your view in the app.
Join the discussion: comments and votes are in the free Beloud app.